“ANAMORELIN HCL - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Cancer Cachexia in 7 Major Markets. A detailed picture of the ANAMORELIN HCL in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Adlumiz (Anamorelin HCl) is being developed by Helsinn Group and Ono Pharmaceutical. In January 2021, ONO received the manufacturing and marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”), a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan. In accordance with a license agreement in force with Helsinn Healthcare SA (a company of the Helsinn Group), ONO has exclusive rights to develop and commercialize Anamorelin in Japan, South Korea and Taiwan. Helsinn retains full rights in the rest of the world.
Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ANAMORELIN HCL.
• The report contains forecasted sales for ANAMORELIN HCL till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Cancer Cachexia.
• The report also features the SWOT analysis with analyst insights and key findings of ANAMORELIN HCL.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ANAMORELIN HCL Analytical Perspective by DelveInsight
• In-depth ANAMORELIN HCL Market Assessment
This report provides a detailed market assessment of ANAMORELIN HCL in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
• ANAMORELIN HCL Clinical Assessment
The report provides the clinical trials information of ANAMORELIN HCL covering trial interventions, trial conditions, trial status, start and completion dates.
• In the coming years, the market scenario for Cancer Cachexia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence ANAMORELIN HCL dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Cancer Cachexia are giving market competition to ANAMORELIN HCL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ANAMORELIN HCL.
• Our in-depth analysis of the forecasted sales data of ANAMORELIN HCL from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ANAMORELIN HCL.
• Which company is developing ANAMORELIN HCL along with the phase of the clinical study?
• What is the technology utilized in the development of ANAMORELIN HCL?
• What is the product type, route of administration and mechanism of action of ANAMORELIN HCL?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ANAMORELIN HCL development?
• What are the key designations that have been granted to ANAMORELIN HCL?
• What is the forecasted market scenario of ANAMORELIN HCL?
• What is the history of ANAMORELIN HCL and what is its future?
• What is the forecasted sales of ANAMORELIN HCL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to ANAMORELIN HCL?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?